The question of whether ‘Polivy,’ a B-cell lymphoma treatment, will be listed for insurance reimbursements this year is garnering significant attention.

According to industry sources, Roche Korea’s Polivy (polatuzumab vedotin), a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), is expected to be presented to the Health Insurance Review and Assessment Service (HIRA)’s Cancer Disease Review Committee on the 31st.

Previously, in 2021, Polivy made an initial attempt to obtain reimbursement listing for its third-line treatment as a combination therapy with BR therapy (bendamustine/rituximab). However, Polivy did not receive approval from the Cancer Disease Rev